Cyprazepam is a benzodiazepine tranquilizer, developed by Warner-Lambert Pharmaceutical Company in the 1960s. The combination of cyprazepam with pentaerythrityl tetranitrate was found advantageous for the treatment of angina pectoris.

LEIOPYRROLE is an antispasmodic agent.

LANIQUIDAR is a P-glycoprotein inhibitor. It was used in trials studying the treatment of breast cancer.

Difencloxazine is a tranquilizing agent.

Brinazarone (SR33557) is a calcium channel blocker, that inhibits acid sphingomyelinase activity and enhances ricin-A chain immunotoxin activity. Brinazarone may act, much like perhexiline, by disturbing membrane lipid composition through their inhibitory action on lysosomal phospholipid hydrolases, such as acid sphingomyelinase, leading to modifications in intracellular routing and to subsequent degradation of ricin-A chain immunotoxins.

Levosemotiadil is an S-enantiomer of semotiadil. It is an antiarrhythmic drug with sodium and calcium channel blocking action, as well as potassium blocking activity. Levosemotiadil is bound strongly and enantioselectively to human serum albumin and human alpha1-acid glycoprotein. Since levosemotiadil is hydrophobic basic drug, it is likely that this drug is also bound to lipoprotein in human plasma. Levosemotiadil might be effective in prevention of lethal arrhythmias. It was shown, that levosemotiadil prevented ventricular fibrillation in 64% of the high-risk animals. Heart rate responses to myocardial ischemia and to graded doses of isoproterenol were blunted by the high dose of levosemotiadil. Levosemotiadil had been in phase II clinical trials by Santen Pharmaceutical for the treatment of arrhythmias. However, this study was discontinued.

Mefenidil has been reported to be a selective cerebral vasodilator. It significantly increased cerebral blood flow (without stimulation of O2 uptake) and lowered cerebral vascular resistance without having significant effects in other circulatory regions. Increase in cerebral blood flow is not mediated via the beta-adrenergic receptor as the effect was not blocked by propranolol. However, the clinical usefulness of mefenidil as a cerebral vasodilator may be limited by the accompanying arterial hypotension due to systemic vasodilation, which was most prominent in heart and gut.